Navigation Links
Study Reaffirms Superiority of Trofile(TM) Assay
Date:12/19/2007

ume operations at commercially reasonable costs; expected reliance on a few customers for the majority of our revenues; the annual renewal of certain customer agreements; actual market acceptance of our products and adoption of our technological approach and products by pharmaceutical and biotechnology companies; our estimate of the size of our markets; our estimates of the levels of demand for our products; the impact of competition; the timing and ultimate size of pharmaceutical company clinical trials; whether payers will authorize reimbursement for our products and services and the amount of such reimbursement that may be allowed; whether the FDA or any other agency will decide to further regulate our products or services, including Trofile; whether the draft guidance on Multivariate Index Assays issued by FDA will be subsequently determined to apply to our current or planned products; whether we will encounter problems or delays in automating our processes; the ultimate validity and enforceability of our patent applications and patents; the possible infringement of the intellectual property of others; whether licenses to third party technology will be available; whether we are able to build brand loyalty and expand revenues; restrictions on the conduct of our business imposed by the Pfizer, Merrill Lynch and other debt agreements; the impact of additional dilution if our convertible debt is converted to equity; and whether we will be able to raise sufficient capital in the future, if required. For a discussion of other factors that may cause actual events to differ from those projected, please refer to our most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission. We do not undertake, and specifically disclaim any obligation, to revise any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of s
'/>"/>
SOURCE Monogram Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... and SAN JOSE, California , January 15, ... developing antibody-drug conjugates for cancer, today announced the appointment of ... Dr Reynolds has over 20 years, development experience gained in ... Seattle Genetics. "I am delighted to welcome Tom ...
(Date:1/15/2014)... 2014 A study has been launched to ... 1 track could help to tackle the problem of obesity. ... (a GP surgery based in Stowmarket) and academics at University ... Telemetry technology, which is inspired by equipment used to ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains ... these latent viruses is the Epstein Barr Virus (EBV), and ... (RA) is a chronic inflammatory disease that destroys the body’s ... RA patients have high concentrations of EBV DNA in their ...
(Date:1/15/2014)... Freeslate, Inc ., the leading provider of ... one of India’s top five pharmaceutical companies, has received ... for high throughput solid form screening. , Lupin, ... range of quality, affordable generic and branded formulations and ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... N.J., Oct. 8 Managed Health Care,Associates, Inc. ... that it plans to open the 2008 MHA ... Secretary, Health and Human Services,(2001-2005), former four-term Governor ... Independent Chairman, Deloitte,Center for Health Solutions. Marking the ...
... announced today that it has entered into a ... producer of infant,formula products including the Similac(R) Advance(R) ... and ARA supplier for all of its,infant formula ... with,Abbott having the right to terminate the arrangement ...
... patients to benefit from rapid, long-lasting symptom control with ... ... fumarate -, NAPA, Calif., Oct. 8 Dey, L.P., ... the launch of Perforomist(TM),(formoterol fumarate) Inhalation Solution, which will be ...
Cached Biology Technology:MHA Announces: Tommy Thompson to be Keynote Speaker at The MHA 5th Annual Business Summit 2Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott 2Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 2Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 3Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 4Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 5Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 6
(Date:4/23/2014)... the first cause of dementia and affects some 400,000 ... yet been found. One of the reasons for this ... which cause alterations in nerve transmissions and the loss ... Researchers from the Institute of Neuroscience at the Universitat ... in memory consolidation and were able to develop a ...
(Date:4/23/2014)... April 23, 2014 A biomedical engineer at the ... innovative technology to make blood transfusions safer. His work ... National Institutes of Health (NIH). , Blood transfusions ... of modern medicine,s absolute necessities. Without them, for instance, ... transfusions are perfect, however. There,s strong evidence that transfusions ...
(Date:4/23/2014)... used to read quickly. It involves visual searching ... and/ or sentences. Similarly to humans, biological systems ... genetic information. Genes that need to be read ... encoding message, the easier it will be to ... de Cincia (IGC, Portugal) and Centre for Molecular ...
Breaking Biology News(10 mins):Loss of memory in Alzheimer's mice models reversed through gene therapy 2UH biomedical engineer works to make blood transfusions safer 2UH biomedical engineer works to make blood transfusions safer 3Cell division speed influences gene architecture 2
... the oil industry will need more refined tools for discoveries ... say. One such tool is a new sediment curve ... the Paleozoic Era 542 to 251 million years ago, scientists ... . The sediment curve covers the entire Paleozoic Era. ...
... his dog to salivate in anticipation of food when ... certain behaviors when enticed with different smells. Researchers at ... of Hong Kong and the National Institute of Standards ... the interval between the signal, or odor, and the ...
... Exposure to Bisphenol A (BPA), phthalates and flame retardants ... humans and laboratory animals. A special section in the ... Plastic World" provides critical new research on environmental contaminants ... products contain "endocrine disrupting chemicals" that can block the ...
Cached Biology News:Paleozoic 'sediment curve' provides new tool for tracking sea-floor sediment movements 2Moths with a nose for learning 26 environmental research studies reveal critical health risks from plastic 2
... jetSI-ENDO is an easy-to-use siRNA transfection reagent ... endogenous genes in a variety of cell ... with an optimized, straightforward protocol. High levels ... obtained following transfection of 20 to 100 ...
... is a tetramethylrhodamine-conjugated jetSI-ENDO (excitation ... 580 nm), the powerful siRNA ... used to determine the transfection ... delivery and trafficking of siRNAs. ...
... in a Morris Water Maze. Tracks up ... sequence of trials.The Spatial Behavior line is a ... camera, frame grabber, and feature extraction software and ... up to 6 moving animals. Software automatically ...
... GEA Diessel fermentation systems for cultivation of ... provided manufacturers of bio-pharmaceutical products maximum performance ... For microbial and cell fermentation 10 L ... dead-leg areas ,*Fully automated control system ...
Biology Products: